Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Highly purified Th17 cells from BDC2.5NOD mice convert into Th1-like cells in NOD/SCID recipient mice
David Bending, Hugo De La Peña, Marc Veldhoen, Jenny M. Phillips, Catherine Uyttenhove, Brigitta Stockinger, Anne Cooke
David Bending, Hugo De La Peña, Marc Veldhoen, Jenny M. Phillips, Catherine Uyttenhove, Brigitta Stockinger, Anne Cooke
View: Text | PDF
Research Article Immunology

Highly purified Th17 cells from BDC2.5NOD mice convert into Th1-like cells in NOD/SCID recipient mice

  • Text
  • PDF
Abstract

Th17 cells are involved in the pathogenesis of many autoimmune diseases, but it is not clear whether they play a pathogenic role in type 1 diabetes. Here we investigated whether mouse Th17 cells with specificity for an islet antigen can induce diabetes upon transfer into NOD/SCID recipient mice. Induction of diabetes in NOD/SCID mice via adoptive transfer of Th1 cells from BDC2.5 transgenic mice was prevented by treatment of the recipient mice with a neutralizing IFN-γ–specific antibody. This result suggested a major role of Th1 cells in the induction of disease in this model of type 1 diabetes. Nevertheless, transfer of highly purified Th17 cells from BDC2.5 transgenic mice caused diabetes in NOD/SCID recipients with similar rates of onset as in transfer of Th1 cells. However, treatment with neutralizing IL-17–specific antibodies did not prevent disease. Instead, the transferred Th17 cells, completely devoid of IFN-γ at the time of transfer, rapidly converted to secrete IFN-γ in the NOD/SCID recipients. Purified Th17 cells also upregulated Tbet and secreted IFN-γ upon exposure to IL-12 in vitro and in vivo in NOD/SCID recipients. These results indicate substantial plasticity of Th17 commitment toward a Th1-like profile.

Authors

David Bending, Hugo De La Peña, Marc Veldhoen, Jenny M. Phillips, Catherine Uyttenhove, Brigitta Stockinger, Anne Cooke

×

Figure 4

Purified Th17 T cells convert in vivo.

Options: View larger image (or click on image) Download as PowerPoint
Purified Th17 T cells convert in vivo.
(A) FACS plots of tetramer staini...
(A) FACS plots of tetramer staining for IL-17 versus IFN-γ before (left dot plot) or after (middle dot plot) purification. IL-17 versus Foxp3 profile of purified cells (right dot plot). Diabetes onset in NOD/SCID recipients of highly purified Th17 cells (filled diamonds) (right panel). Numbers indicate the percentage of cells in each quadrant. (B) Representative FACS plots gated on CD4+Vβ4+ T cells from PLNs, pancreata, and mesenteric lymph nodes (MLNs) 8 days after transfer of highly purified Th17 cells, showing IL-17 versus IFN-γ intracellular staining. Numbers indicate the percentage of cells in each quadrant (A and B). (C) Summary graphs showing the percentage of cells producing IL-17, IL-17 plus IFN-γ, or IFN-γ alone. Horizontal bars represent mean percentage of CD4+ cells positive for stated cytokines from 6 samples, and individual symbols represent percentage of CD4+ cells positive for stated cytokines for individual mice. **P < 0.01, Mann-Whitney U test (n = 6). These data are representative of 3 independent experiments.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts